Susceptibilidad genética y aclaramiento viral de la infección por virus de la hepatitis C
DOI:
https://doi.org/10.17533/udea.iatreia.213Palabras clave:
Inmunidad Innata, Patología celular, Polimorfismo genético, Virus de la hepatitis CResumen
El virus de la hepatitis C (VHC) sigue siendo una de las principales causas de hepatitis crónica en el mundo occidental. Del 15 % al 40 % de los individuos con infección aguda por VHC logran el aclaramiento viral espontáneo; sin embargo, los factores y variables asociadas a este fenómeno no están completamente descritas. El análisis de los mecanismos de patogénesis de la infección por VHC es indispensable para identificar los factores y variables implicadas en el aclaramiento espontáneo o en la persistencia de la infección. En algunos estudios se han documentado los factores del huésped asociados al aclaramiento viral espontáneo durante la infección aguda, entre ellos el polimorfismo del gen de la interleucina -28 (IL28B) que codifica para el interferón lambda 3 (IFNL3). El objetivo de este artículo es realizar una revisión de la literatura sobre la fisiopatología de la infección por el VHC y describir la evidencia acerca del papel de los polimorfismos en el gen IL28B y su impacto en el proceso de aclaramiento viral espontáneo, así como en otros aspectos de la historia natural y el tratamiento de la infección.
Descargas
Citas
(1) Bennett JE, Mandell GL, Douglas RG, editores. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Elsevier; 2015 [consultado 2022 May 31]. https://doi.org/10.1016/C2012-1-00075-6b
(2) Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol [Internet]. 1993 [consultado 2022 Feb 28]; 74(11):2391–9. https://doi.org/10.1099/0022-1317-74-11-2391
(3) Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL. Hepatitis C virus genotype 7, a new genotype originating from central Africa. J Clin Microbiol [Internet]. 2015 [consultado 2022 Feb 28]; 53(3):967-72. https://doi.org/10.1128/JCM.02831-14
(4) Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, et al. Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification. Open forum Infect Dis [Internet]. 2019 [consultado 2022 Feb 28]; 6(3):ofz076. https://doi.org/10.1093/OFID/OFZ076
(5) Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol [Internet]. 2004 [consultado 2022 Feb 28]; 85(11):3173–88. https://doi.org/10.1099/VIR.0.80401-0/CITE/REFWORKS
(6) Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol [Internet]. 2017 [consultado 2022 Feb 28]; 2(3):161-76. https://doi.org/10.1016/S2468-1253(16)30181-9
(7) Cuenta de Alto Costo. Informe de seguimiento de casos con hepatitis c crónica en el marco de la estrategia de negociación y compra centralizada de medicamentos [Internet]. 2019 [consultado 2022 Jun 16]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/CAC/032019-cac3350-informe-hepatitisc.pdf
(8) Ministerio de Salud y Protección Social. Rendición de cuentas: informe de gestión 2019 [Internet]. 2020 [cited 2022 Jun 16]. Disponible en: https://www.minsalud.gov.co/RID/informe-gestion2019-marzo30-2020-t.pdf
(9) Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host–Virus Interaction and Mechanisms of Viral Persistence. Cells [Internet]. 2019 [consultado 2022 Feb 28]; 8(4):376. https://doi.org/10.3390/CELLS8040376
(10) Alter MJ, Mast EE, Moyer LA, Margolis HS. Hepatitis C. Infect Dis Clin North Am [Internet]. 1998 [consultado 2022 Jun 16];12(1):13–26. https://doi.org/10.1016/S0891-5520(05)70405-0
(11) Mohd-Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology [Internet]. 2013 [consultado 2022 Feb 28]; 57(4):1333–42. https://doi.org/10.1002/HEP.26141
(12) Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, et al. Hepatitis C virus infection. Nat Rev Dis Prim [Internet]. 2017;3:17006. https://doi.org/10.1038/nrdp.2017.6
(13) Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis [Internet]. 2002 [consultado 2022 Feb 28]; 34(6):831–7. https://doi.org/10.1086/339042
(14) European AIDS Clinical Society, European Association for the Study of the Liver, Société de Pathologie Infectieuse de Langue Française, Agence national de recherches sur le sida et les hépatites virales, European AIDS Treatment Group, International AIDS Society, et al. [Short statement of the first European consensus conference on the treatment of chronic hepatitis C and B in HIV co-infected patients]. Med Mal Infect [Internet]. 2005 Mar;35(3):109–20. https://doi.org/10.1016/j.medmal.2005.03.015
(15) Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med [Internet]. 2014 Mar 4 [consultado 2022 Feb 28]; 160(5):293. https://doi.org/10.7326/M13-1133
(16) Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology [Internet]. 2008 [consultado 2022 Jun 5];134(6):1699–714. https://doi.org/10.1053/J.GASTRO.2008.02.069
(17) Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol [Internet]. 2001 May 1 [consultado 2022 Abr 19]; 34(5):730–9. https://doi.org/10.1016/S0168-8278(00)00097-0
(18) Lesens O, Deschênes M, Steben M, Bélanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis [Internet]. 1999 [consultado 2022 Jun 5]; 179(5):1254–8. https://doi.org/10.1086/314720
(19) Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology [Internet]. 2001 [consultado 2022 Feb 28]; 33(2):321–7. https://doi.org/10.1053/JHEP.2001.22112
(20) Liang JT, Jeffers L, Reddy RK, Cheinquer H, Findor A, Medina MDE, et al. Fulminant or Subfulminant Non-A, Non-B Viral Hepatitis: The Role of Hepatitis C and E Viruses. Gastroenterology [Internet]. 1993;104(2):566–562. https://doi.org/10.1016/0016-5085(93)90426-d
(21) Farci P, Alter HJ, Shimoda A, Govindarajan S, Cheung LC, Melpolder JC, et al. Hepatitis C Virus–Associated Fulminant Hepatic Failure. N Engl J Med [Internet]. 2009 Aug 20 [consultado 2022 Feb 28];335(9):631–4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/8687517/
(22) Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis [Internet]. 2005 [consultado 2022 Feb 28]; 40(7):951–8. https://doi.org/10.1086/428578
(23) Kaplan DE. Hepatitis C virus. Ann Intern Med [Internet]. 2020;173(5):ITC33–48. https://doi.org/10.7326/AITC202009010
(24) Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology [Internet]. 2008 Aug [consultado 2022 Abr 19]; 48(2):418–31. https://doi.org/10.1002/hep.22375
(25) Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M. Innate immunity induced by composition-dependent RIG-I recognition of Hepatitis C virus RNA. Nature [Internet]. 2008 [consultado 2022 Feb 28];454(7203):523–7. https://doi.org/10.1038/nature07106
(26) Terilli RR, Cox AL. Immunity and Hepatitis C: A Review. Curr HIV/AIDS Rep [Internet]. 2013 [consultado 2022 Feb 28]; 10(1):51-8. https://doi.org/10.1007/s11904-012-0146-4
(27) Zhou JH, Wang YN, Chang QY, Ma P, Hu Y, Cao X. Type III interferons in viral infection and antiviral immunity. Cell Physiol Biochem [Internet]. 2018;51(1):173–85. https://doi.org/10.1159/000495172
(28) Peña-López BO, Romero-Bohórquez AR, Rincón-Orozco B. Importancia de los interferones tipo I en la respuesta inmune antiviral contra el Virus del Papiloma Humano. Salud UIS [Internet]. 2021 Oct 18;53(1): e21034. https://doi.org/10.18273/Saluduis.53.e:21034
(29) Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res [Internet]. 2004 Ago [consultado 2022 Abr 20]; 24(8):439–54. https://doi.org/10.1089/1079990041689665
(30) Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol [Internet]. 2003 Ene [consultado 2022 Abr 20]; 4(1):69–77. https://doi.org/10.1038/NI875
(31) Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko S V, Macdonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology [Internet]. 2006 Dic [consultado 2022 Feb 21]; 131(6):1887–98. https://doi.org/10.1053/J.GASTRO.2006.09.052
(32) Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem [Internet]. 1998 [consultado 2022 Abr 20]; 67:227–64. https://doi.org/10.1146/ANNUREV.BIOCHEM.67.1.227
(33) Bolen CR, Ding S, Robek MD, Kleinstein SH. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology [Internet]. 2014 [consultado 2022 Abr 20]; 59(4):1262–72. https://doi.org/10.1002/hep.26657
(34) Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature [Internet]. 2005 [consultado 2022 Jun 2]; 436(7053):939–45. https://doi.org/10.1038/nature04078
(35) Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest [Internet]. 2009 Jul 1 [consultado 2022 Feb 28]; 119(7):1745. https://doi.org/10.1172/JCI39133
(36) Heim MH. Innate immunity and HCV. J Hepatol [Internet]. 2013;58(3):564–74. http://dx.doi.org/10.1016/j.jhep.2012.10.005
(37) Li K, Foy E, Ferreon JC, Nakamura M, Ferreon ACM, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A [Internet]. 2005 Feb 22 [consultado 2022 Jun 2]; 102(8):2992–7. https://doi.org/10.1073/PNAS.0408824102
(38) Geiss GK, Carter VS, He Y, Kwieciszewski BK, Holzman T, Korth MJ, et al. Gene Expression Profiling of the Cellular Transcriptional Network Regulated by Alpha/Beta Interferon and Its Partial Attenuation by the Hepatitis C Virus Nonstructural 5A Protein. J Virol [Internet]. 2003 Jun [consultado 2022 Jun 2]; 77(11):6367-75. https://doi.org/10.1128/JVI.77.11.6367-6375.2003
(39) Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A [Internet]. 2002 Mar 3 [consultado 2022 Jun 2]; 99(5):3081-6. https://doi.org/10.1073/PNAS.052712599
(40) Thimme R. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. J Hepatol [Internet]. 2021 Ene 1 [consultado 2022 Jun 2]; 74(1):220–9. https://doi.org/10.1016/J.JHEP.2020.09.022
(41) Miri HH, Fazeli P, Ali-Hassanzadeh M, Bemani P, Kabelitz D, Kalantar K. Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis. Arch Virol [Internet]. 2021;166(9):2469–78. https://doi.org/10.1007/s00705-021-05141-8
(42) Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus HHS Public Access. Nature [Internet]. 2009 [consultado 2022 Feb 28]; 461(7265):798–801. https://doi.org/10.1038/nature08463
(43) Shebl FM, Pfeiffer RM, Buckett D, Muchmore B, Chen S, Dotrang M, et al. IL28B rs12979860 genotype and spontaneous clearance of hepatitis c virus in a multi-ethnic cohort of injection drug users: Evidence for a supra-additive association. J Infect Dis [Internet]. 2011;204(12):1843–7. https://doi.org/10.1093/infdis/jir647
(44) Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology [Internet]. 2014;59(1):109–20. https://doi.org/10.1002/hep.26639
(45) Swiatek-Koscielna B, Kałuzna E, Strauss E, Nowak J, Bereszynska I, Gowin E, et al. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol [Internet]. 2017;23(21):3815–24. https://doi.org/10.3748/wjg.v23.i21.3815
(46) Sakhaee F, Ghazanfari M, Vaziri F, Jamnani FR, Davari M, Gharibzadeh S, et al. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. Infect Genet Evol [Internet]. 2017 Oct 1 [consultado 2022 Jun 5]; 54:330–7. https://doi.org/10.1016/J.MEEGID.2017.07.023
(47) Hassanien KS, El-Sayed ESM, Ismail RS, Zakarya ZM, Helal GK. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients. J Clin Pharm Ther [Internet]. 2021 Ago 1 [consultado 2022 Nov 23]; 46(4):942–9. https://doi.org/10.1111/JCPT.13417
(48) Silva AMV da, Alvarado-Arnez LE, Azamor T, Batista-Silva LR, Leal-Calvo T, Bezerra OC de L, et al. Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha. Front Cell Infect Microbiol [Internet]. 2021;11:656393. https://doi.org/10.3389/fcimb.2021.656393
(49) Chayama K, Hayes CN. Interleukin-28B polymorphisms and hepatitis C virus clearance. Genome Med [Internet]. 2013 Ene 29 [consultado 2022 Abr 20]; 5(1):1–3. https://doi.org/10.1186/GM410/METRICS
(50) Massoud O. Hepatitis C: looking into the future. Expert Rev Gastroenterol Hepatol [Internet]. 2020 [consultado 2022 Nov 23]; 14(5):367–74. https://doi.org/101080/1747412420201746641
(51) Zaki SM, Ahmed HS, Yousif MM, Awad EM. Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients. Trop Med Infect Dis [Internet]. 2022;7(9):230 https://doi.org/101080/10.3390/tropicalmed7090230
(52) Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous Clearance of Chronic Hepatitis C Virus Infection Is Associated With Appearance of Neutralizing Antibodies and Reversal of T-Cell Exhaustion. J Infect Dis [Internet]. 2012 [consultado 2022 Abr 20]; 205(5):763-71. https://doi.org/10.1093/infdis/jir835
(53) Kamal SM, Kassim SK, Ahmed AI, Mahmoud S, Bahnasy KA, Hafez TA, et al. Host and viral determinants of the outcome of exposure to HCV infection genotype 4: A large longitudinal study. Am J Gastroenterol [Internet]. 2014 Feb [consultado 2022 Abr 20]; 109(2):199–211. https://doi.org/10.1038/AJG.2013.427
(54) van den Berg CHBS, Grady BPX, Schinkel J, van de Laar T, Molenkamp R, van Houdt R, et al. Female sex and IL28b, a synergism for spontaneous viral clearance in hepatitis c virus (HCV) seroconverters from a community-based cohort. PLoS One [Internet]. 2011;6(11):e27555. https://doi.org/10.1371/journal.pone.0027555
(55) Bouman A, Jan Heineman M, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update [Internet]. 2005 Jul 1 [consultado 2022 Abr 21]; 11(4):411–23. https://doi.org/10.1093/HUMUPD/DMI008
(56) Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis [Internet]. 2010 May [consultado 2022 Apr 21]; 10(5):338-49. https://doi.org/10.1016/S1473-3099(10)70049-9
(57) InvivoGen. InvivoGen Insight Newsletter: Interferon λs [Internet]. 2018 [consultado 2022 Apr 20]. Disponible en: https://www.researchgate.net/institution/InvivoGen/post/New-InvivoGen-Insight-Newsletter-on-Interferon-ls-guardians-of-the-front-lines-5b8675f25801f247f144dc98
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Iatreia
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
Los artículos publicados en la revista están disponibles para ser utilizados bajo la licencia Creative Commons, específicamente son de Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.
Los trabajos enviados deben ser inéditos y suministrados exclusivamente a la Revista; se exige al autor que envía sus contribuciones presentar los formatos: presentación de artículo y responsabilidad de autoría completamente diligenciados.